HomeCompareMCRNF vs JNJ

MCRNF vs JNJ: Dividend Comparison 2026

MCRNF yields 3.32% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.9K in total portfolio value· pulled ahead in Year 6
10 years
MCRNF
MCRNF
● Live price
3.32%
Share price
$1.40
Annual div
$0.05
5Y div CAGR
-45.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$0.79
Full MCRNF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MCRNF vs JNJ

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCRNFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCRNF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCRNF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCRNF
Annual income on $10K today (after 15% tax)
$282.39/yr
After 10yr DRIP, annual income (after tax)
$0.67/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCRNF + JNJ for your $10,000?

MCRNF: 50%JNJ: 50%
100% JNJ50/50100% MCRNF
Portfolio after 10yr
$25.3K
Annual income
$2,345.10/yr
Blended yield
9.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MCRNF
No analyst data
Altman Z
15.4
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCRNF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCRNFJNJ
Forward yield3.32%2.13%
Annual dividend / share$0.05$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-45.5%28%
Portfolio after 10y$20.4K$30.3K
Annual income after 10y$0.79$4,689.40
Total dividends collected$402.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MCRNF vs JNJ ($10,000, DRIP)

YearMCRNF PortfolioMCRNF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,881$181.06$10,592$272.30+$289.00MCRNF
2$11,743$100.35$11,289$357.73+$454.00MCRNF
3$12,620$55.16$12,123$472.89+$497.00MCRNF
4$13,534$30.20$13,141$629.86+$393.00MCRNF
5$14,498$16.49$14,408$846.81+$90.00MCRNF
6← crossover$15,522$9.00$16,021$1,151.60$499.00JNJ
7$16,613$4.91$18,122$1,588.22$1.5KJNJ
8$17,779$2.68$20,930$2,228.20$3.2KJNJ
9$19,025$1.46$24,792$3,191.91$5.8KJNJ
10$20,357$0.79$30,274$4,689.40$9.9KJNJ

MCRNF vs JNJ: Complete Analysis 2026

MCRNFStock

Micro-Mechanics (Holdings) Ltd. designs, manufactures, and markets high precision parts and tools used in applications for the wafer-fabrication and assembly processes of the semiconductor industry. It operates through five segments: Singapore, Malaysia, The Philippines, USA, and China. The company offers die attach-pick-up products, such as rubber tips, high-temp plastic tools, tungsten carbide die collets, sensor assemblies, and vacuum wand tools; die attach-dispensing products, including dispense nozzle adaptors, dispense nozzles, pen dispense assemblies, writing pen nozzle tips, and epoxy stamping tools; and die attach-die ejection products comprising ejector needles, needle holders/pepper pots, and needle holder seals. It also provides thermosonic bonding products that include clamps and electronic flame off products; ultrasonic bonding products comprising clamps, bearing base assemblies, anvils, and wire cutters; and encapsulation products consisting of BGA dispensing nozzles, dispensing manifolds, pump screws, and O-rings. In addition, the company manufactures precision parts and assemblies on a contract basis for OEMs. Further, it manufactures precision components and modules. The company was founded in 1983 and is headquartered in Singapore.

Full MCRNF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MCRNF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCRNF vs SCHDMCRNF vs JEPIMCRNF vs OMCRNF vs KOMCRNF vs MAINMCRNF vs ABBVMCRNF vs MRKMCRNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.